Summary
Regeneration of large bone defects is an unmet medical need with a high socio-economic burden, affecting millions of people worldwide. To overcome the limitations of existing solutions for bone replacement, we developed GreenBone, our pioneering acellular synthetic bone graft obtained from proprietary biomorphic transformation process of Rattan wood. By mimicking the chemical composition and 3D pore structure of natural human bone, we are able to provide an optimum microenvironment capable of driving inductive bone performance and de-novo bone mineralisation response at the ectopic site.
With the EIC accelerator grant first, we aim to disrupt the bone graft market by introducing the first technologically advanced spinal implant that combines the needed mechanical strength with enhanced regenerative capacity. We aim to bring our product to the spinal market segment in 2025, reaching 10% market share in 2030 and growing our company team to more than 40 skilled professionals.
With the EIC accelerator grant first, we aim to disrupt the bone graft market by introducing the first technologically advanced spinal implant that combines the needed mechanical strength with enhanced regenerative capacity. We aim to bring our product to the spinal market segment in 2025, reaching 10% market share in 2030 and growing our company team to more than 40 skilled professionals.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190178589 |
| Start date: | 01-09-2022 |
| End date: | 31-08-2025 |
| Total budget - Public funding: | 3 511 612,50 Euro - 2 458 128,00 Euro |
Cordis data
Original description
Regeneration of large bone defects is an unmet medical need with a high socio-economic burden, affecting millions of people worldwide. To overcome the limitations of existing solutions for bone replacement, we developed GreenBone, our pioneering acellular synthetic bone graft obtained from proprietary biomorphic transformation process of Rattan wood. By mimicking the chemical composition and 3D pore structure of natural human bone, we are able to provide an optimum microenvironment capable of driving inductive bone performance and de-novo bone mineralisation response at the ectopic site.With the EIC accelerator grant first, we aim to disrupt the bone graft market by introducing the first technologically advanced spinal implant that combines the needed mechanical strength with enhanced regenerative capacity. We aim to bring our product to the spinal market segment in 2025, reaching 10% market share in 2030 and growing our company team to more than 40 skilled professionals.
Status
SIGNEDCall topic
HORIZON-EIC-2021-ACCELERATOROPEN-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
